Boxer Capital’s iTeos Therapeutics ITOS Stock Holding History

Boxer Capital’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,946,915	Closed	-$30.1M	–	23
2024 Q3	$30.1M	Hold	2,946,915	–	–	1.48%	17
2024 Q2	$43.7M	Buy	2,946,915 +1,142,857	+63%	+$16.4M	2.3%	13
2024 Q1	$24.6M	Hold	1,804,058	–	–	1.22%	25
2023 Q4	$19.8M	Hold	1,804,058	–	–	0.98%	28
2023 Q3	$19.8M	Sell	1,804,058 -350,000	-16%	-$4.48M	1.05%	32
2023 Q2	$28.5M	Hold	2,154,058	–	–	1.32%	27
2023 Q1	$29.3M	Hold	2,154,058	–	–	1.44%	21
2022 Q4	$42.1M	Hold	2,154,058	–	–	2.22%	13
2022 Q3	$41M	Hold	2,154,058	–	–	2.31%	13
2022 Q2	$44.4M	Sell	2,154,058 -1,038,000	-33%	-$24.6M	2.81%	11
2022 Q1	$103M	Sell	3,192,058 -1,152,958	-27%	-$41.9M	5.28%	3
2021 Q4	$202M	Hold	4,345,016	–	–	7.86%	3
2021 Q3	$117M	Hold	4,345,016	–	–	4.1%	4
2021 Q2	$111M	Hold	4,345,016	–	–	3.93%	4
2021 Q1	$149M	Hold	4,345,016	–	–	5.04%	5
2020 Q4	$147M	Hold	4,345,016	–	–	4.72%	4
2020 Q3	$107M	Buy	+4,345,016	New	+$117M	3.7%	5

Other funds holding ITOS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Boxer Capital's ITOS Position: Q4 2024 in Review

Boxer Capital sold out of iTeos Therapeutics (ITOS) in Q4 2024, closing a stake of 2,946,915 shares — an estimated $30.1M sold.

Boxer Capital first reported a position in ITOS in Q3 2020 and held it in 17 quarters. The position peaked at $202M in Q4 2021. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2024.

Boxer Capital reported no remaining iTeos Therapeutics position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 2,946,915 iTeos Therapeutics shares in Q4 2024, an estimated $30.1M.
Boxer Capital first reported a position in iTeos Therapeutics in Q3 2020 and held it in 17 quarters.
Boxer Capital's iTeos Therapeutics position peaked at $202M in Q4 2021.
137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.